Elske Hoornenborg1, Liza Coyer2, Roel C A Achterbergh2, Amy Matser2, Maarten F Schim van der Loeff3, Anders Boyd2, Yvonne T H P van Duijnhoven2, Sylvia Bruisten3, Paul Oostvogel2, Udi Davidovich3, Arjan Hogewoning2, Maria Prins3, Henry J C de Vries4. 1. Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, Netherlands. Electronic address: ehoornenborg@ggd.amsterdam.nl. 2. Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, Netherlands. 3. Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, Netherlands; Department of Infectious Diseases, Amsterdam Infection and Immunity Institute (AI&II), Amsterdam University Medical Centers, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. 4. Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, Netherlands; Department of Dermatology, Amsterdam Infection and Immunity Institute (AI&II), Amsterdam University Medical Centers, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Abstract
BACKGROUND: Pre-exposure prophylaxis (PrEP) for HIV might induce risk compensation, defined as increased sexual risk behaviour leading to increased incidence of bacterial sexually transmitted infections (STIs). We examined the incidence of HIV, STIs, and sexual behaviour after initiating daily and event-driven PrEP. METHODS: AMPrEP is a demonstration study that assessed the incidence of HIV and bacterial STIs and sexual behaviour among PrEP users at the STI clinic of the Public Health Service of Amsterdam (Amsterdam, the Netherlands). Eligible adults (aged ≥18 years) were HIV-negative men who have sex with men (MSM) and transgender people who had reported one or more of the following in the previous 6 months: condomless anal sex with casual partners, at least one bacterial STI, use of post-exposure prophylaxis after a sexual risk incident, or an HIV-positive sexual partner with detectable viral load. Participants were given a choice of daily PrEP or event-driven PrEP regimens. Participants were seen every 3 months for HIV and STI testing. Participants also completed self-administered questionnaires about sexual behaviour at each visit. Over the first 2 years, we assessed the number and incidence rate of HIV and chlamydia, gonorrhoea, and syphilis, including STIs diagnosed in between study visits and assessed changes in incidence over time using piecewise exponential survival models. The number of sexual acts and sexual partners were also analysed and changes over time were assessed using negative binomial regression models. This study is ongoing; the data cutoff for this analysis was June 30, 2018. FINDINGS: Between Aug 3, 2015, and May 31, 2016, 376 participants were recruited, of whom nine participants were lost to follow-up, thus 367 participants were included in the analysis. Overall, 365 MSM and two transgender women were included, contributing 681·7 person-years of follow-up. At enrolment, 269 (73%) of 367 participants chose daily PrEP and 98 (27%) participants chose event-driven PrEP. Two individuals in the daily PrEP group became HIV-positive; overall HIV incidence rate was 0·30 per 100 person-years (95% CI 0·07-1·19). 253 participants were diagnosed with one or more STI during the first 2 years (incidence rate 90·4 per 100 person-years). STI incidence did not change over time (adjusted incidence rate ratio [aIRR] 1·00 per 3 month follow-up, 95% CI 0·93-1·07). More than a quarter of all STIs were diagnosed from tests done in between study visits. STI incidence was lower in the event-driven PrEP group than the daily PrEP group (aIRR 0·59, 95% CI 0·46-0·75). The number of condomless anal sex acts with casual partners per 3 months increased, but the number of partners and sex acts remained stable. INTERPRETATION: Although the overall incidence of STIs did not change during 2 years of PrEP use, the incidence of STIs was higher among participants using daily PrEP than those using event-driven PrEP, which is likely a result of differences in sexual behaviour. This finding suggests the need to tailor STI prevention interventions according to behavioural profiles. FUNDING: ZonMw, H-TEAM, Internal GGD research funds, Aidsfonds, Stichting AmsterdamDiner Foundation, Gilead Sciences, Janssen Pharmaceutica, M A C AIDS Fund, and ViiV Healthcare.
BACKGROUND: Pre-exposure prophylaxis (PrEP) for HIV might induce risk compensation, defined as increased sexual risk behaviour leading to increased incidence of bacterial sexually transmitted infections (STIs). We examined the incidence of HIV, STIs, and sexual behaviour after initiating daily and event-driven PrEP. METHODS: AMPrEP is a demonstration study that assessed the incidence of HIV and bacterial STIs and sexual behaviour among PrEP users at the STI clinic of the Public Health Service of Amsterdam (Amsterdam, the Netherlands). Eligible adults (aged ≥18 years) were HIV-negative men who have sex with men (MSM) and transgender people who had reported one or more of the following in the previous 6 months: condomless anal sex with casual partners, at least one bacterial STI, use of post-exposure prophylaxis after a sexual risk incident, or an HIV-positive sexual partner with detectable viral load. Participants were given a choice of daily PrEP or event-driven PrEP regimens. Participants were seen every 3 months for HIV and STI testing. Participants also completed self-administered questionnaires about sexual behaviour at each visit. Over the first 2 years, we assessed the number and incidence rate of HIV and chlamydia, gonorrhoea, and syphilis, including STIs diagnosed in between study visits and assessed changes in incidence over time using piecewise exponential survival models. The number of sexual acts and sexual partners were also analysed and changes over time were assessed using negative binomial regression models. This study is ongoing; the data cutoff for this analysis was June 30, 2018. FINDINGS: Between Aug 3, 2015, and May 31, 2016, 376 participants were recruited, of whom nine participants were lost to follow-up, thus 367 participants were included in the analysis. Overall, 365 MSM and two transgender women were included, contributing 681·7 person-years of follow-up. At enrolment, 269 (73%) of 367 participants chose daily PrEP and 98 (27%) participants chose event-driven PrEP. Two individuals in the daily PrEP group became HIV-positive; overall HIV incidence rate was 0·30 per 100 person-years (95% CI 0·07-1·19). 253 participants were diagnosed with one or more STI during the first 2 years (incidence rate 90·4 per 100 person-years). STI incidence did not change over time (adjusted incidence rate ratio [aIRR] 1·00 per 3 month follow-up, 95% CI 0·93-1·07). More than a quarter of all STIs were diagnosed from tests done in between study visits. STI incidence was lower in the event-driven PrEP group than the daily PrEP group (aIRR 0·59, 95% CI 0·46-0·75). The number of condomless anal sex acts with casual partners per 3 months increased, but the number of partners and sex acts remained stable. INTERPRETATION: Although the overall incidence of STIs did not change during 2 years of PrEP use, the incidence of STIs was higher among participants using daily PrEP than those using event-driven PrEP, which is likely a result of differences in sexual behaviour. This finding suggests the need to tailor STI prevention interventions according to behavioural profiles. FUNDING: ZonMw, H-TEAM, Internal GGD research funds, Aidsfonds, Stichting AmsterdamDiner Foundation, Gilead Sciences, Janssen Pharmaceutica, M A C AIDS Fund, and ViiV Healthcare.
Authors: Daniel R Newman; James Matthias; Mohammad M Rahman; Antoine Brantley; Thomas A Peterman Journal: AIDS Patient Care STDS Date: 2021-11 Impact factor: 5.078
Authors: Alexandra Blenkinsop; Mélodie Monod; Ard van Sighem; Nikos Pantazis; Daniela Bezemer; Eline Op de Coul; Thijs van de Laar; Christophe Fraser; Maria Prins; Peter Reiss; Godelieve J de Bree; Oliver Ratmann Journal: Elife Date: 2022-08-03 Impact factor: 8.713
Authors: Susan P Buchbinder; Aaron J Siegler; Kenneth Coleman; Eric Vittinghoff; Gretchen Wilde; Annie Lockard; Hyman Scott; Peter L Anderson; Nicole Laborde; Ariane van der Straten; Richard H Christie; Michelle Marlborough; Albert Y Liu Journal: AIDS Behav Date: 2022-08-19
Authors: Dana Ogaz; Louise Logan; Tyrone J Curtis; Lorraine McDonagh; Luis Guerra; Daniel Bradshaw; Poorvi Patel; Chiara Macri; Gary Murphy; O Noel Gill; Anne M Johnson; Anthony Nardone; Fiona Burns Journal: BMC Public Health Date: 2022-06-03 Impact factor: 4.135
Authors: Steven P Philpot; Dean Murphy; Curtis Chan; Bridget Haire; Doug Fraser; Andrew E Grulich; Benjamin R Bavinton Journal: Sex Res Social Policy Date: 2022-06-17
Authors: August Eubanks; Bakary Coulibaly; Bintou Dembélé Keita; Camille Anoma; Ter Tiero Elias Dah; Ephrem Mensah; Gwenaëlle Maradan; Michel Bourrelly; Marion Mora; Lucas Riegel; Daniela Rojas Castro; Issifou Yaya; Bruno Spire; Christian Laurent; Luis Sagaon-Teyssier Journal: AIDS Behav Date: 2022-04-25
Authors: Hanne M L Zimmermann; Lisa R Postma; Roel C A Achterbergh; Thijs Reyniers; Maarten F Schim van der Loeff; Maria Prins; Henry J C de Vries; Elske Hoornenborg; Udi Davidovich Journal: Arch Sex Behav Date: 2021-02-22
Authors: Elizabeth M Kiefer; Kallan S Ross; Abigail C Santos; Maya R Barney; Timothy J McCormick; Dominic C Chow; Cecilia M Shikuma Journal: Hawaii J Health Soc Welf Date: 2021-07